Another cohort saw a statistically significant increase in ROR1 levels after patients developed resistance to the BCL2 inhibitor venetoclax [54], offering a potential link between ROR1 and drug resistance in CLL. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.